Paclitaxel as first- or second-line treatment for HIV-negative Kaposi’s sarcoma: a retrospective study of 58 patients
Background: Paclitaxel has recently been approved for AIDS-related Kaposi’s sarcoma (KS) and there is much interest also in HIV-negative KS. Objective: To assess the safety and effectiveness of intravenous paclitaxel in the treatment of non-HIV-associated KS. Method: A retrospective database analysi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-02-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2019.1590520 |